Example: Heart Attack

Search clinical trials for: Fludarabine

Total 1654 results

NCT03832127

Not yet recruiting

Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients

Conditions: Myeloma
NCT01472055

Unknown status

Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation

Conditions: Acute Leukemia; Chronic Leukemia; Severe Aplastic Anemia
NCT04425655

Not yet recruiting

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Conditions: Acute Myeloid Leukemia, Adult; AML; AML, Adult
NCT02718755

Withdrawn

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Conditions: Hematologic Malignancy
NCT02514083

Active, not recruiting

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT02926586

Unknown status

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

Conditions: Acute Myeloid Leukemia; Core-Binding Factor
NCT03754933

Recruiting

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Conditions: Recurrent Head and Neck Cancer
NCT03696537

Active, not recruiting

IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT

Conditions: Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphocytic Leukemia; Myelodysplastic Syndromes
NCT02128945

Completed

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies

Conditions: Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients
NCT03813147

Recruiting

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome
NCT01310179

Completed

Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

Conditions: Head and Neck Cancer
NCT01096992

Completed

Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)

Conditions: Leukemia
NCT02024308

Unknown status

AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy

Conditions: Acute Myeloid Leukemia; AML1-ETO Fusion Protein Expression
NCT00208975

Terminated

Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab

Conditions: Lymphoma
NCT00882323

Unknown status

Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)

Conditions: Aplastic Anemia
NCT01186458

Terminated

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Conditions: Lymphoma, Non-Hodgkin
NCT03342196

Recruiting

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

Conditions: Leukemia
NCT02649764

Active, not recruiting

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Chronic Myelomonocytic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory High Risk Myelodysplastic Syndrome
NCT00278265

Terminated

Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

Conditions: T-Cell Large Granular Lymphocytic Leukemia
NCT00004246

Completed

Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx

Conditions: Head and Neck Cancer
NCT01019317

Completed

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Conditions: Leukemia; AML; MDS; CML
NCT00502905

Completed

Busulfan and Fludarabine in Patients With AML and MDS

Conditions: Leukemia
NCT03016988

Not yet recruiting

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT04526795

Not yet recruiting

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent T-Cell Prolymphocytic Leukemia; Refractory Acute Biphenotypic Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory T-Cell Prolymphocytic Leukemia
NCT00506857

Completed

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

Conditions: Hematologic Malignancies